ArticleCancer medicine2023
Early Termination of Oncology Clinical Trials in the United States.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Letter to the editor on: "Discontinuation and nonpublication of osteosarcoma clinical trials: a cross-sectional analysis of ClinicalTrials.gov data".European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
- Moving toward precision communication in pediatric oncology clinical trials: An outline of a conceptual framework to support caregiver decision-making.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Recruiting children and young people with vision impairment for clinical research - experience from the SeeMyLife study.BMC medical research methodology · 2026Article
- Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials.Current oncology (Toronto, Ont.) · 2026Article
- Success rates of American clinical oncology trials by geographic factors.Scientific reports · 2026Article
- Occurrence and management of premature clinical trial termination: a survey of UK healthcare professionals.Trials · 2026Article
- Approaches in analyzing predictors of trial failure: a scoping review and meta-epidemiological study.BMC medical research methodology · 2026Article
- Characteristics and potential predictors of prematurely terminated interventional clinical trials for ovarian cancer in the ClinicalTrials.gov database.BMC cancer · 2025Article
- Determinants of clinical trial failure in multiple sclerosis: insights from ClinicalTrials.gov.Research square · 2025Article
- UK paediatric clinical trial protocols: A review of guidance for participant management and care in the event of premature termination.Clinical trials (London, England) · 2025Review
- Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals.Contemporary clinical trials communications · 2025Article
- Early termination and nonpublication of phase III/IV melanoma clinical trials: a cross-sectional study.Proceedings (Baylor University. Medical Center) · 2025Article
- Overcoming challenges of recruiting cancer patients into clinical trials: insights from a randomized trial of app-based smoking cessation interventions.American journal of cancer research · 2025Article
- Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.Targeted oncology · 2024Article
- Simplifying informed consent as a universal precaution.Scientific reports · 2024Article
- Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges.JCO global oncology · 2024Article
- Analysis of Terminated Hand and Wrist-Related Clinical Trials.Journal of hand surgery global online · 2023Article
- Early Termination of Oncology Clinical Trials in the United States.Cancer medicine · 2023Article
- Institutional Review Board Obligations Regarding Study Funding Sufficiency.Ethics & human researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the rate of early trial discontinuation of oncology trials and reasons for early termination, to assess potential trends in rates of oncology trial termination, and to perform a comprehensive analysis of predictors of early termination. This study intends to inform efforts in improving efficiency of the oncology clinical trial enterprise.
methodsWe conducted a cross-sectional study of interventional cancer clinical trials registered in ClinicalTrials.gov database from September 27, 2007 to June 30, 2015, with at least one site listed in the United States. We evaluated predictors of early trial termination using Fisher exact or χ
resultsOf 8687 trials, 22.74% (n = 1975) were terminated trials. Rates of early trial termination appeared stable over the study. Statistically significant univariate predictors of early termination for any reason include cancer category, phase, funding source, location, and age. In multivariable analysis, trials spanning multiple cancer categories and international trials were less likely to terminate early whereas phase 2 trials and trials funded by academia/foundation were more likely to terminate early. The most common reason for early termination was "Other, Multiple Reasons, or Unknown" (36.9%), followed by accrual issues (34.5%). In multivariate analysis among all terminated trials, supportive care trials, phase 2 trials, and non-industry funded trials had significantly higher odds of trial discontinuation specifically due to poor accrual.
conclusionIn this national sample of cancer clinical trials, early trial discontinuation was common. Many factors influenced early trial termination with poor accrual being a common reason. Specific trial features are associated with differential likelihood of early trial termination for any reason and for early trial termination due to poor accrual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.